Date |
Company |
Compound |
Disease |
Type of agreement |
Therapeutic area |
Type of Information |
2017-07-03 |
AstraZeneca (UK) Recordati (Italy) |
Seloken®/Seloken® ZOK (metoprolol succinate) and associated
Logimax® fixed dose combination (metoprolol succinate and felodipine) treatments |
hypertension, angina, heart failure |
product acquisition |
Cardiovascular diseases |
Product acquisition |
2017-07-02 |
Exscientia (UK) GSK (UK) |
novel and selective small molecules for up to 10 disease-related targets using an artificial intelligence platform |
|
collaboration |
|
Collaboration agreement |
2017-06-30 |
Molmed (Italy) TTY Biopharm |
Zalmoxis® - TK cell therapy |
hematological cancers |
licensing - commercialisation - distribution |
Cancer - Oncology |
Licensing agreement |
2017-06-30 |
Ipsen (France) Saol Therapeutics (USA - GA) |
Dysport® (abobotulinumtoxin A ) |
adult spasticity, pediatric lower limb spasticity |
co-promotion |
Neurological diseases - Neuromuscular diseases |
Co-promotion agreement |
2017-06-30 |
Quantum Genomics (France) |
|
|
nomination |
Cardiovascular diseases |
Nomination |
2017-06-29 |
Abbvie (USA - IL) CytomX (USA - CA) |
Probody™ Drug Conjugates against CD71 including CX-2029 |
|
development - commercialisation |
Cancer - Oncology |
Milestone |
2017-06-29 |
ITeos Therapeutics (Belgium) |
|
|
nomination |
Cancer - Oncology |
Nomination |
2017-06-29 |
TiGenix (Belgium) |
|
|
establishment of a new subsidiary in the US |
|
Establishment of a new subsidiary in the US |
2017-06-29 |
Servier (France) Transgene (France) |
allogenic CAR-T cell therapies |
|
research - R&D |
|
Research agreement |
2017-06-29 |
Horama (France) |
Chief Medical Officer, Head of CMC Regulatory Affairs, Chief Financial Officer |
|
nomination |
Rare diseases - Genetic diseases - Ophtalmological diseases |
Nomination |
2017-06-28 |
Cellectis (France) |
member of the board of directors |
|
nomination |
Cancer - Oncology - Immunological diseases |
Nomination |
2017-06-28 |
Inovio Pharmaceuticals (USA - PA) |
|
|
nomination |
Cancer - Oncology - Infectious diseases |
Nomination |
2017-06-28 |
Sarepta Therapeutics (USA - MA) |
president and chief executive officer |
|
nomination |
Rare diseases - Genetic diseases - Neuromuscular diseases |
Nomination |
2017-06-27 |
Ablynx (Belgium) Merck&Co (USA - NJ) |
Nanobody candidates (including bi- and tri-specifics) directed toward immune checkpoint modulators |
|
research - R&D - licensing |
Cancer - Oncology |
Milestone |
2017-06-27 |
Sarepta Therapeutics (USA - MA) |
|
|
opening of new premises |
Rare diseases - Genetic diseases - Neuromuscular diseases |
Opening of new premises |
2017-06-27 |
Lion Biotechnologies (USA - CA), now Iovance Biotherapeutics (USA - CA) |
|
|
|
Cancer - Oncology |
Restructuring |
2017-06-26 |
University of Cambridge (UK) Genomics England Ltd (UK) Illumina (USA) |
100,000 Genomes Project |
rare genetic diseases, cancers |
collaboration |
Genetic diseases - Rare diseases - Cancer - Oncology |
Collaboration agreement |
2017-06-26 |
Epizyme (USA - MA) Genentech, a member of Roche Group (USA - CA - Switzerland) |
tazemetostat - EPZ-6438 (E7438) and Tecentriq™ (atezolizumab) |
relapsed or refractory diffuse large B-cell lymphoma (DLBCL), non-Hodgkin lymphoma, relapsed/refractory metastatic non-small cell lung cancer (NSCLC) |
clinical research - collaboration |
Cancer - Oncology |
Clinical research agreement |
2017-06-26 |
Takeda Pharmaceutical (Japan) Biological E. (India) |
measles vaccines and acellular pertussis vaccine |
measles, pertussis |
licensing |
Infectious diseases |
Licensing agreement |
2017-06-26 |
Curevac (Germany) |
GMP III and GMP IV facilities |
|
construction of new premises |
|
Construction of new premises |